The effect and tolerance of lonig-term oral administration of small doses of neomvcin as a serum cholesterol reducing agent has been investigated. Sixteen patients were given neomycin sulfate orally for periods varying from 12 to 40.1 months, following control periods of 2.6 to 14.6 months. After an initial daily dose of 2 g of neomycin, the daily dose was varied between 0.5 and 2 g according to response. Average total serum cholesterol concentration.s decreased in each of the 16 patients by 15 to 32%; the average decrease for the group was 22%. The difference was statistically significant in each patienit at the 0.1% level. Serum cholesterol concentrations were maintained at the lower plateau as long as the drug was given. In an additional patient, after administration of neomycin for 2 months there was no change in serum cholesterol concentrations and the study was discontinued. Another developed severe diarrhea, nausea, and abdominal cramps during the first week of the study, so that medication was interrupted.
SUMMARY
The effect and tolerance of lonig-term oral administration of small doses of neomvcin as a serum cholesterol reducing agent has been investigated. Sixteen patients were given neomycin sulfate orally for periods varying from 12 to 40.1 months, following control periods of 2.6 to 14.6 months. After an initial daily dose of 2 g of neomycin, the daily dose was varied between 0.5 and 2 g according to response. Average total serum cholesterol concentration.s decreased in each of the 16 patients by 15 to 32%; the average decrease for the group was 22%. The difference was statistically significant in each patienit at the 0.1% level. Serum cholesterol concentrations were maintained at the lower plateau as long as the drug was given. In an additional patient, after administration of neomycin for 2 months there was no change in serum cholesterol concentrations and the study was discontinued. Another developed severe diarrhea, nausea, and abdominal cramps during the first week of the study, so that medication was interrupted.
No other serious side effects occurred. During the first 2 weeks of medication eight of the 16 patients experienced mild diarrhea or abdominal cramps or both which subsided spontaneously during continued medication. Physical examinations were carried out. kidney and liver functions remained normal, and pathogens were not grown from stool cultures.
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Intestinal bacteria O RAL ADMINISTRATION of nieomycin in daily doses of 0.5 to 2 g reduces the serum cholesterol level in man. The average decline in serum cholesterol concentrations in this laboratory was 21l with daily administration of 1.5 to 2 g of neomycin, whereas smaller doses induced less marked changes.l Neomycin was given for periods varying from 4 to 37 wveeks in these studies, maintaining serum cholesterol levels at a Investigation was supported in part by U. S. Public Health Service Grant HE-07188, and by grants from The Nassau Heart Association and The Americai Heart Associationi. 938 lower plateau than usual for as long as the drug was given. Serum cholesterol returned to control values in each case after administration of neomycin was discontinued. The effect of neomycin on the level of human serum cholesterol has been studied in a number of other laboratories4-11 with essentially similar results. The aim of the present investigation was to study the long-term effectiveness and tolerance of small oral doses of neomycin as a serum cholesterol-reducing agent in a group of ambulatory patients who had normal everyday activities and diet.
Methods
Eighteen patients, 10 males aind eight females, were studied. The age range was from 12 to 62 years at the beginning of the study. Clinical 9340 NEOMYCIN AND SERUM CHOLESTEROL 2 g, then 1 g of neomycin daily. However, the next least marked reduction (16%) occurred in a patient who was given 2 g of the drug throughout the study. For the three patients who had the most marked reduction of serum cholesterol levels (25 to 32%), daily doses varied from 0.5 to 2 g.
An additional patient (A.G., 52 F) was given 2 g of neomycin orally for 2.2 months without appreciable change in the level of serum cholesterol. At this point administration of the drug was discontinued, and it was concluded that neomycin had no effect on the serum cholesterol levels in this subject.
No severe side effects were noted during the administration of the drug. Eight of the 17 patients developed mild diarrhea, abdominal cramps, and mild nausea during the first or second week of the administration of neomycin, which was easily controlled with tincture of paregoric. The administration of neomycin was continued and the symptoms subsided by the end of the second week in each of these patients. They were then completely free of side effects during the remaining part of the study, for periods up to more than 3 years. The weight of all except two patients remained within two pounds variation throughout the study. The first exception was a 12-year-old boy (A.K., 12 M) with familial hypercholesterolemia and xanthomatosis. During same temporary abnormalities. It was then concluded that these abnormalities were not due to the experimental medication, and its administration was continued uninterruptedly. The laboratory values returued to normal spontaneously, and since then neomycin has been given to this patient for an additional year without evidence of clinical or laboratory side effects. This episode had no apparent effect on serum cholesterol levels during the study.
The eighteenth patient in this study, a 37-year-old woman with type II-familial hypercholesterolemia,12 was given 2 g of neomycin daily. During the first week of the administration of the drug she developed severe diarrhea and nausea. The study was interrupted, and no further attempts were made to give her the drug.
Discussion
It is generally accepted that the oral administration of neomycin consistently lowers the concentration of serum cholesterol in man. The results of the present study suggest that the drug is effective for relatively extended periods and that the concentration of serum cholesterol will not return to control levels during medication, even after as long as 3 years. Furthermore, the administration of the drug on a long-term basis in a group of patients with normal activities seems feasible without significant side effects. Serum cholesterol values were abnormally high in 11 patients during control periods. Following the administration of neomycin, the level of serum cholesterol was reduced to values regarded as normal for age and sex in eight of the patients.
A review of the literature on the oral use of neomycin as a serum cholesterol reducing agent is presented in table 2. Including the present study, the effect of the drug on blood cholesterol has been reported to the best of our knowledge in a total of 180 patients. The daily dose of neomycin in these studies varied from 200 mg to 12 g. The medication was continued for 6 A previous report from this laboratory showed that smaller doses of neomycin induced less marked changes of serum cholesterol than the daily administration of 2 g.1
One group of investigators gave 200 mg of neomycin per day orally to patients and reported that this dose had no effect on serum cholesterol.9
Studies on a variety of serum lipids were reported from a number of laboratories during the administration of neomycin. The esterified fraction of serum cholesterol,1-3 6 serum phospholipids,1 2, 6, 7, 9 and total serum lipids" 6 decreased in proportion to total serum cholesterol. The alpha and beta-lipoprotein ratios were not altered by neomycin.3, 6 The variation of serum glycerides was inconsistent in one laboratory7 9; marked reductions of serum triglycerides were reported from another.1' The concentration of free fatty acids Circulation, Volume XXXV, May 1967 was reduced during the administration of the drug.7
The fall in serum cholesterol due to fat free or low fat diets is augmented by administration of neomycin. The addition of neomycin to a regimen of a fat free diet in four patients '6 or to a regimen of a low fat diet in three patients6 resulted in further serum cholesterol reductions of from 14 to 26%, after the dietary regimens had reduced the level of serum cholesterol by 10 to 23% from initial control periods.
The potential toxicity of parenterally administered neomycin has been pointed out repeatedly.'9-22 It is, however, generally accepted that neomycin is poorly absorbed from the gastrointestinal tract. The oral administration of the drug was reported to be well tolerated even in relatively high doses for prolonged periods in patients without kidney disease, and reports on toxic side effects during the oral administration of the drug are scarce. Kunin and associates23 pointed out that patients with renal insufficiency accumulated neomycin in the serum due to decreased renal excretion of the small amounts of drug absorbed which led to serious side effects. Ototoxicity was reported in three adults24-26 and in one infant27 during the oral administration of neomycin. However, the prolonged use of neomycin administered orally in a group of premature infants was well tolerated.28 Dawson and associates29 reported that the daily oral administration of a large dose, 4 to 10 g, of neomycin to 20 patients with liver disease was well tolerated for periods up to 10 months. In a subsequent study Last and Sherlock24 gave similar large doses of the drug orally to 27 patients with liver disease for periods up to 140 days. One patient developed ototoxicity during the study. Monilia overgrowth was reported in surprisingly few cases during the administration of neomycin. Permanent audiotoxicity and temporary nephrotoxicity, due to oral administration of the drug, was reported in one patient by Greenberg and Momary. Clinical Research: Method, Support, and Ethic Those of us who are engaged in medical education and research fear the treason of the clerks, who wish to have everything tidy and circumscribed and who forget that the oak sheds ten thousand acorns to produce another tree and the fish spawns a million eggs to maintain the race of fishes. Research requires a spirit, not of prodigality but of magnificence, using that word as it was used by the Greeks, who thought that three virtues are essential if a democracy is to remain great-proper ambition, magnificence, and greatness of spirit....
There is at present a good deal of uninspired clinical research, research of which we may say, in Lord Macaulay's words, "The inquiry may amuse us but the decision leaves us no wiser." Apart from ethical problems, therefore, it is a good thing that clinical science and human experiment should recently have come under sharp scrutiny. There is need to bring together in frank cooperation the people who do the experiments and those who submit to them. If 
